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Background & Aims 
 
Increased visceral adiposity is considered the hallmark of the metabolic syndrome, whose hepatic 
manifestation is nonalcoholic fatty liver disease (NAFLD), although a subset of patients does not have 
visceral obesity. Our study aimed to compare metabolic alterations and liver damage in patients with 
NAFLD with and without visceral obesity. 
 
Methods 
 
Four hundred and thirty one consecutive patients with liver biopsy-confirmed NAFLD were divided in three 
groups according to waist circumference, the simplest surrogate marker of visceral obesity. One hundred 
and thirty three patients (31%) had a waist circumference ⩽94 (males) and ⩽80 cm (females) (group A), 
157 (36%) between 94 and 102, and 80 and 88 (B), and the remaining 141 (33%) had values higher than 102 
and 88 cm (C). 
 
Results 
 
Significant trends for older age, higher prevalence of female gender, lower HDL, higher triglycerides, altered 
glucose metabolism, hypertension, and metabolic syndrome were observed with increasing visceral 
adiposity. In contrast, non-alcoholic steatohepatitis (NASH) detected in 55% and 72% of patients with 
normal and increased waist circumference, respectively, and the presence of fibrosis ⩾2 were not 
associated with visceral adiposity. Alanine aminotransferase (ALT), ferritin, HOMA-IR >4, and severe 
steatosis were independently associated with NASH, whereas ferritin and impaired glucose tolerance were 
associated with fibrosis ⩾2. 
 
Conclusions 
 
Patients with normal waist circumference, despite milder metabolic alterations, may have NASH and are at 
risk of developing fibrosis, suggesting that once NAFLD is present, visceral obesity is not a major 
determinant of liver damage severity. 
 
Abbreviations 
NAFLD, nonalcoholic fatty liver disease;  
NASH, nonalcoholic steatohepatitis;  
HOMA-IR, homeostatic model assessment insulin resistance index;  
BMI, body mass index;  
ALT, alanine aminotransferase;  
GGT, gamma-glutamyltransferase;  
OGTT, oral glucose tolerance test;  
OR, odd ratio;  
adj, adjusted;  
CI, confidence intervals 
 
 
Introduction 
 
Increased visceral adiposity is considered the hallmark of the metabolic syndrome, a clinical condition 
characterized by increased cardiovascular risk driven by raised blood pressure, dyslipidemia, and altered 
glucose regulation. However, in recent years a subset of patients has been identified, with normal body 
weight and similar metabolic disturbances (so called metabolically-obese, normal weight (MONW) cases), 
who also shares a similar cardiovascular risk [1]. 
 
The various clinical expressions of nonalcoholic fatty liver disease (NAFLD), from pure fatty liver to 
nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis, and eventually hepatocellular carcinoma are 
considered a manifestation of the metabolic syndrome. Also among NAFLD cases, a subset of patients does 
not present with visceral obesity, but insulin resistance remains the common soil of both the metabolic 
syndrome and NAFLD, largely independent of increased fat mass. In a prospective study, subjects with 
NAFLD and elevated ALT were reported to be at higher risk of developing diabetes and the metabolic 
syndrome than subjects without NAFLD, and the risk was driven by waist circumference, hypertension, and 
insulin resistance [2]. 
 
Conflicting evidence has been reported on the complex relationship between visceral fat mass, insulin 
resistance and NAFLD. The severity of insulin resistance is a determinant of liver damage progression in 
NAFLD [3] and adipose tissue insulin resistance was recently proposed to underlie the pathogenesis of liver 
damage [4], [5] and [6]. Accordingly, visceral obesity might represent a non-invasive marker of disease 
severity in the general NAFLD population. However, adequately powered studies assessing the association 
between waist circumference and liver damage are not available. 
 
Waist circumference remains the simplest and most widely used surrogate marker of visceral adiposity [7] 
and [8], and other proposed surrogate markers, including the recent perihepatic adipose tissue thickness at 
ultrasonography, skin thickness, and dorsal cervical fat are scarcely used in the clinical setting [9] and [10]. 
The aim of this study was to compare metabolic alterations and severity of liver damage in patients with 
NAFLD with and without increased visceral obesity, simply estimated by the easily available waist 
circumference measure, to define which are the variables associated with hepatic and extrahepatic 
morbidities. 
 
 
Methods 
 
Patients 
 
We merged the databases of consecutive patients with liver biopsy-confirmed NAFLD observed in four Liver 
Units. All consecutive patients who underwent liver biopsy between January 2003 and June 2009 were 
included in the study unless the tissue sample size was <1.7 cm. The final cohort was made up of 431 cases. 
Most of these patients had been included in a previous multicenter Italian study [11]. Other causes of liver 
diseases (viral, autoimmune, cholestatic, drug-induced, hereditary hemochromatosis, Wilson’s disease) 
were excluded. In all patients, daily alcohol intake was lower than 20 g (confirmed by at least one family 
member). Clinical and laboratory data were collected at the time of liver biopsy (Table 1). 
 
Table 1.  
Characteristics of patients with NAFLD, divided according to abdominal circumference (group A<94 
and <80 cm, group B⩾94 <102 and ⩾80 <88, group C⩾102 and ⩾88 cm in man and woman, 
respectively). 
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Mean ± SD or number of cases and (%). p-Values from ANOVA or chi-square test. 
Patients with clinical or imaging evidence of decompensated cirrhosis were excluded from the study. Liver 
biopsy was performed in 323 (75%) patients because of abnormalities in liver function tests, whereas in the 
remaining 108 either a persistent increase in serum ferritin or a long-lasting history of steatosis was the 
main reason for biopsy. 
 
All patients had given informed, written consent to data handling according to a protocol approved by the 
Senior Staff Committee of our Institutions, a board comparable to an Institutional Review Board. 
 
 
Methods 
 
The database contained data on life habits, clinical and pharmacological history, BMI, waist circumference 
(measured in a standing position at the level of the umbilicus) and arterial blood pressure (defined as the 
mean of the second and third reading of three consecutive blood pressure measurements), blood count, 
liver function tests (AST, ALT, gamma-glutamyltransferase (GGT), serum albumin, platelets count, bilirubin), 
fasting glucose and insulin, total and HDL cholesterol, triglycerides, and uric acid. All tests were determined 
by standard laboratory procedures; insulin by a commercially purchased radioimmunoassay (RIA, Biochem 
Immunosystems, Bologna, Italy). The upper normal limit of ALT levels was set at 40 U/L. The diagnosis of 
the metabolic syndrome was carried out according to ATPIII criteria [12], and based on the presence of 3 or 
more of the following criteria: (1) fasting glucose ⩾100 mg/dl, (2) central obesity (waist circumference >102 
cm (men) and >88 cm (women), (3) arterial pressure ⩾130/85 mmHg or treatment for hypertension, (4) 
triglycerides levels ⩾150 mg/dl or use of fibrates, (5) HDL-cholesterol <40 mg/dl (men) and <50 mg/dl 
(women). 
 
Insulin resistance was evaluated according to the homeostatic model assessment insulin resistance index 
(HOMA-IR) [13], as fasting serum insulin (in μIU/ml) multiplied by fasting serum glucose (in mMol/L), 
divided by 22.5. Oral glucose tolerance test (OGTT) was performed with 75 g of glucose according to World 
Health Organization criteria in 382 (89%) patients. 
 
The presence of diabetes mellitus (fasting glucose ⩾126 mg/dl, 120-min glucose ⩾200 during OGTT, or 
treatment with antidiabetic drugs), obesity (BMI >30 kg/m2) and overweight (BMI, 25–29.9 kg/m2) were 
defined using standard criteria. 
 
 
 
 
Liver histology 
 
Liver biopsies were routinely processed and read by a single pathologist in each center. To control for 
biopsy size, the length of the biopsy was measured with a hand ruler, and the number of portal areas on a 
cross-section was counted. The minimum biopsy size was 1.7 cm and the number of portal areas 10. The 
diagnosis of NASH was based on the pathologist’s overall impression according to Brunt criteria [14], 
modified by Kleiner [15]. The stage of fibrosis was scored based on the 5-point scale (stage 0, absence of 
fibrosis; stage 1, perisinusoidal or portal fibrosis; stage 2, perisinusoidal and portal/periportal fibrosis; stage 
3, septal or bridging fibrosis; stage, 4 cirrhosis). The severity of steatosis was graded from 1 to 3 according 
to the percentage of cells with fatty droplets (1: 6–33%, 2: 33–66%, and 3 >66%). 
 
Statistical analysis 
 
Results are expressed as means ± standard deviations for continuous variables and as frequencies for 
categorical variables. p-Values from ANOVA or chi-square test were considered statistically significant if 
⩽0.05. Logistic regression analyses were performed to calculate odds ratios (OR), and their 95% confidence 
intervals (CI) for two outcomes, NASH, and fibrosis grade ⩾2 (the latter value was chosen because of the 
relatively mild fibrosis detected in our series) [11]. Variables significant at univariate analyses or of a priori 
interest were entered into the final multivariate model. Independent variables were categorized according 
to quartiles (ALT), tertiles (ferritin), or following commonly used cut-offs. In particular, waist circumference 
was categorized in three groups, (group A <94 and <80 cm, group B ⩾94 <102 and ⩾80 <88, group C ⩾102 
and ⩾88 cm in man and woman, respectively) [12] and [16]; steatosis was graded from 1 to 3 [11]. Age was 
divided in decades, and HOMA-IR categories were arbitrarily chosen as follows: <2.5, absence of insulin 
resistance; 2.5–4.0, moderate insulin resistance; >4, severe insulin resistance. p-Values for linear trends 
were calculated for ordinal variables. All statistical analyses were performed with the Stata 11 software 
[17]. 
 
Results 
 
The characteristics of patients subdivided in three groups according to waist circumference are shown in 
Table 1. At increasing waist circumference, patients were progressively older, and more frequently of 
female gender, had a higher BMI, lower HDL-cholesterol, higher triglycerides, and higher fasting glucose, 
insulin, and HOMA-IR. In addition, there was an increased prevalence of impaired glucose tolerance and 
diabetes, arterial hypertension, and metabolic syndrome, which paralleled the increase in visceral obesity. 
 
The prevalence of severe steatosis and NASH increased with higher waist circumference, whereas the 
prevalence of severe fibrosis was not significantly associated with waist girth. At multivariate analysis, after 
adjustment for referral center, NASH and fibrosis were not significantly associated with waist 
circumference evaluated either as a categorized or as a continuous variable. The variables independently 
associated with NASH were ALT levels, serum ferritin and HOMA-IR in the upper tertile, and steatosis grade 
3 (Table 2); those associated with fibrosis ⩾2 (Table 3) were serum ferritin >380 ng/ml and impaired 
glucose tolerance. 
Table 2.  
Risk of NASH according to selected clinical variables. 
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∗Each variable adjusted for the others in the table and for center. 
Table 3.  
Risk of severe fibrosis according to selected clinical variables. 
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∗Each variable adjusted for the others in the table and for center. 
 
Discussion 
 
In this study performed in a large series of well-characterized Italian patients with histologically-proven 
NAFLD, we analyzed metabolic alterations and liver damage in relation to the presence of visceral obesity. 
Our results indicate that waist circumference, an easily available surrogate marker of visceral adiposity, was 
strongly correlated with metabolic alterations and severity of steatosis, but not with NASH and liver 
fibrosis. We conclude that not yet elucidated mechanisms, including genetic factors [18], [19], [20], [21], 
[22] and [23] not quantifiable by the simple measure of waist circumference, are responsible for liver 
disease progression in patients with NAFLD and that the risk of severe liver damage should not be 
underestimated in lean subjects. 
 
In our study on subjects of Caucasian origin, we used the three values of waist circumference proposed by 
International agencies and observed a progressive increase in the prevalence of metabolic alterations, with 
increasing abdominal adiposity, in patients without visceral adiposity having milder metabolic 
derangements, similar to previous results [12], [16], [24] and [25]. 
 
As expected, steatosis and visceral adiposity were significantly correlated, with severe steatosis (grade 3) 
being much more prevalent in patients with the largest waist circumference. Although the prevalence of 
NASH increased with increasing waist circumference, being 55% and 72% in lean and obese subjects, 
respectively, no relation was observed between waist circumference and NASH at multivariate analysis. 
 
More controversial is the relation between fibrosis and visceral obesity. In an attempt to identify the 
variables predictive of fibrosis, several authors have investigated a variety of markers including 
demographic, anthropometric, biochemical, and clinical parameters, but no conclusive results have been 
reached [26], [27], [28], [29], [30] and [31]. Variables related to glucose control (impaired glucose 
metabolism/diabetes) were more frequently identified [8], [26], [27] and [28] as predictive of fibrosis, 
whereas the relation of increased BMI with fibrosis was uncertain. In our series, we did not find any 
association between BMI, which reflects total body adiposity, and the severity of fibrosis; whereas liver cell 
necrosis (as detected by ALT values) and the presence of altered glucose metabolism predicted the 
presence of fibrosis ⩾2, as previously reported. 
 
Noteworthy, in children with NAFLD [32], [33] and [34], waist circumference was the only component of 
the metabolic syndrome associated with liver fibrosis. It is possible that this reflects the lower number of 
confounding factors in pediatric patients, i.e. the shorter duration of liver disease and obesity, as well as 
differences in unhealthy lifestyle habits, comorbidities, and drugs. Interestingly, Cheung et al. [4] reported 
that dorso-cervical lipohypertrophy, but not waist circumference, was associated with the severity of 
histology in adult NAFLD, suggesting that specific fat depots are pivotal in liver fibrosis. 
 
Morbid obesity is a paradigm of the uncertain relation between visceral obesity and liver damage in 
patients with NAFLD. In a recent prospective study [35], only 15–20% of patients with grade III obesity, 
despite the high frequency of steatosis (80%) and marked insulin resistance, had NASH; mild fibrosis was 
detected in less than 25% of cases, with only 4% having fibrosis ⩾2, suggesting that factors unrelated to 
insulin resistance (cytokines, toxic effect of lipid molecules, gut microflora, oxidative stress, etc.) are 
necessary to promote liver disease progression. Progression of hepatic fibrosis was documented 5 years 
after bariatric surgery, despite a marked weight loss, decreased insulin resistance, improved steatosis and 
reduced NASH prevalence. However, since fibrosis was relatively mild in obese patients submitted to 
bariatric surgery as well as in our patients with NAFLD [11], it remains to be defined whether the 
correlation with visceral adiposity changes in relation to the stage of fibrosis. 
 
 
 
A role of adipose tissue insulin resistance has recently been proposed to explain the pathogenesis and the 
progression of histological liver damage in lean and obese patients with NASH [36], but it is not defined 
which adipose tissue is the culprit. For example, pericardial fat is more tightly associated with early 
coronary artery disease than waist circumference [37]. Whether specific subcomponents of body fat 
recently defined as ectopic fat [38], and not quantifiable by waist circumference, are involved in liver 
damage progression, remains to be defined. 
 
Interestingly, a third-world NAFLD phenotype has recently been described in which subtle values of 
increased adiposity, not overt adiposity, predispose to NAFLD [39]. This finding could open new 
perspectives to understand the origin of NAFLD in lean subjects. 
 
It is possible that genetic factors predisposing to adipose tissue dysfunction may be involved in the 
pathogenesis of IR in relatively lean patients who develop NAFLD and progressive liver disease. 
 
However, we did not find an over-representation of genetic factors that we previously demonstrated to 
influence either IR (ENPP1 and IRS-1 polymorphisms [21]) or the severity of steatosis (PNPLA3 
polymorphisms [22]), and, consequently, the severity of liver damage in relatively “lean” compared to 
obese patients with NAFLD, except for a decreased prevalence in patients from UK. Interestingly, the C282Y 
mutation in the HFE gene, associated with mild iron overload in patients with NALFD, was more frequent in 
lean than in obese subjects [40] and [41], suggesting that a mild increase in liver iron may lead to 
augmented lipotoxicity of the fat accumulated in the liver or alter adipocytes function. However, the results 
of additional ongoing studies are required to clarify this issue, and it should be noted that the majority of 
genetic factors possibly involved is presently still unknown. 
 
In conclusion, visceral adiposity influences the manifestations of the metabolic syndrome but not the 
severity of liver damage in patients with NAFLD. As a consequence, also lean patients with NAFLD, despite 
an apparently milder metabolic involvement, should be carefully screened and monitored for the presence 
of NASH and severe liver fibrosis. 
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Supplementary data 
  
Supplementary Table.   
Supplementary table. Prevalence of genetic factors previously associated with susceptibility to 
progressive liver fibrosis in patients with NAFLD with increased adiposity  (waist circumference 
>102 cm and > 88 cm in male and female respectively or BMI>27.5 if waist circumference not 
available) and normal adiposity (waist circumference <102 cm and > 88 cm in male and female 
respectively or BMI<27.5). 
 
Genetic variant Paper Patients 
evaluated 
Prevalence of genetic 
variant 
p 
   Increased 
adiposity 
Normal 
adiposity  
 
HFE C282Y Valenti, Fracanzani, et al; 
Gastroenterology 2010, [40] 
587 19/307 
(6.2%) 
30/280 
(10.8%) 
0.053 
HFE H63D Valenti, Fracanzani, et al; 
Gastroenterology 2010, [40] 
587 96/307 
(31.3%) 
90/280 
(32.1%) 
ns 
Beta globin 
mutations 
Valenti, Canavesi, et al;  
J Hepatol 2010, [42] 
274 10/114 
(8.1%) 
15/148 
(10.1%) 
ns 
IRS-1 G972R 
Italy 
Dongiovanni, Valenti, et al; 
 Gut 2010, [21] 
239 22/112 
(19.2%) 
28/127 
(22.0 %) 
ns 
IRS-1 G972R 
UK 
Dongiovanni, Valenti, et al; 
 Gut 2010, [21] 
328 31/304 
(10.3%) 
0/24 ns 
ENPP1 K121Q 
Italy 
Dongiovanni, Valenti, et al; 
 Gut 2010, [21] 
239 21/112 
(28.9%) 
31/127 
(24.4%) 
ns 
ENPP1 K121Q 
UK 
Dongiovanni, Valenti, et al; 
 Gut 2010, [21] 
328 88/304 
(29.0%) 
1/24 
(4.2%) 
0.007 
PNPLA3 I148M Valenti, Al-Serri, et al; 
 Hepatology 2010, [22] 
592 200/459 
(43.1%) 
55/133 
(41.4%) 
ns 
 
Ns: not significant. 
 
Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, et al. Beta-globin mutations are 
associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J 
Hepatol 2010 
 
Prevalence of genetic factors previously associated with susceptibility to progressive liver fibrosis in 
patients with NAFLD with increased adiposity (waist circumference >102 and >88 cm in male and female 
respectively or BMI >27.5 if waist circumference not available) and normal adiposity (waist circumference 
<102 and >88 cm in male and female respectively or BMI <27.5). 
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